Doron Therapeutics Raises $11M Series A to Progress Biologic Regenerative Osteoarthritis Drug into Phase 3 Clinical StudiesCHAPEL HILL, NC, November 25, 2024-- Doron Therapeutics, a clinical-stage biotech company focusing on degenerative musculoskeletal conditions, today announced it has successfully raised an aggregate $11 million as an initial Series A round to take MOTYS™ into Phase 3 clinical studies.

Doron Therapeutics筹集了1100万美元的A系列资金，将生物再生性骨关节炎药物推进3期临床研究北卡罗来纳州教堂山，2024年11月25日——Doron Therapeutics是一家专注于退行性肌肉骨骼疾病的临床阶段生物技术公司，今天宣布，它已成功筹集了1100万美元，作为将MOTYS™纳入3期临床研究的第一轮A系列资金。

SPRIM Global Investments (SGI), a prominent health sciences investment firm, is leading the round..

SPRIM Global Investments（SGI）是一家著名的健康科学投资公司，正在领导这一轮。。

Doron's most advanced product, MOTYS™, is an intra-articular biologic drug developed for the management of symptomatic knee osteoarthritis. Data from a Phase 2 clinical trial were recently presented on podium at the Osteoarthritis Research Society International (OARSI) World Congress 2024 in Vienna, Austria - where MOTYS™ was identified as a highly promising program to address the significant impact of debilitating osteoarthritis..

Doron最先进的产品MOTYS™是一种关节内生物药物，用于治疗症状性膝关节骨性关节炎。。。

With compelling pre-clinical evidence of superiority when compared to currently available therapies, including steroids and hyaluronic acid, a robust CMC package and clinical data from over 350 patients, MOTYS™ is being developed to provide potent and durable effects from a single injection.

与目前可用的疗法（包括类固醇和透明质酸），强大的CMC包和350多名患者的临床数据相比，MOTYS™具有令人信服的临床前优越性证据，正在开发中，可通过单次注射提供有效且持久的效果。

As part of the Series A financing, Doron is also adding two new board members. Karen Zaderej, who previously served as chief executive officer and as chairman of the board of directors of Axogen Inc. from 2010, led the company's transformation from a start-up to a public company. Her experience advancing Avance Nerve Graft®, a biologically active human tissue graft, through BLA submission will be invaluable to Doron.

作为A系列融资的一部分，多龙还增加了两名新的董事会成员。2010年起担任Axogen Inc.首席执行官兼董事会主席的Karen Zaderej领导了该公司从初创公司向上市公司的转型。她通过提交BLA推进Avance Nerve Graft®（一种具有生物活性的人体组织移植物）的经验对多伦来说将是无价的。

Also joining the board is Tassos Konstantinou, SPRIM's managing director, an investment professional with life science venture capital and business development experience that brings a broad and diversified global perspective..

SPRIM董事总经理塔索斯·康斯坦蒂努（Tassos Konstantinou）也加入了董事会，他是一名拥有生命科学风险投资和业务发展经验的投资专业人士，具有广阔而多元化的全球视野。。

'We are excited for Doron to join our portfolio of companies - and see a great opportunity for their program to be successful and disrupt the vast and growing global market of osteoarthritis,' said Michael Shleifer, managing partner of SPRIM.

SPRIM管理合伙人迈克尔·施莱弗（MichaelShleifer）说：“我们很高兴多龙加入我们的公司组合，并看到他们的计划取得成功并扰乱巨大且不断增长的全球骨关节炎市场的绝佳机会。”。

'We are grateful to our Series A investors, for their confidence in our initiative,' said Alessandra Pavesio, chief executive officer and co-founder of Doron. 'This is an exciting time for Doron as we progress our lead product into Phase 3 clinical studies. The unmet need for non-surgical interventions in osteoarthritis is immense and growing.

多龙首席执行官兼联合创始人亚历桑德拉·帕维西奥（AlessandraPavesio）说，我们感谢A轮投资者对我们的计划充满信心这对多龙来说是一个激动人心的时刻，因为我们将主导产品推进了3期临床研究。对骨关节炎非手术干预的需求尚未得到满足，并且正在增长。

We believe MOTYS™ will allow patients to have reduced pain and regain function, allowing them the opportunity to get back to healthy and active lives.'.

我们相信MOTYS™将使患者减轻疼痛并恢复功能，使他们有机会恢复健康和积极的生活。”。

About Osteoarthritis

关于骨关节炎

OA is the most common form of arthritis, affecting millions of people worldwide. It occurs when the protective cartilage that cushions the ends of the bones wears down over time. This can lead to pain, stiffness, and swelling in the joints, most commonly in the knees, hips, hands and spine. Risk factors include age, sex, obesity and a history of participation in active sports.

OA是最常见的关节炎形式，影响全球数百万人。当保护骨骼末端的保护性软骨随着时间的推移而磨损时，就会发生这种情况。。危险因素包括年龄，性别，肥胖和参与积极运动的历史。

Women are more likely to develop OA..

女性更容易患OA。。

About Doron Therapeutics

关于Doron Therapeutics

Doron Therapeutics is a clinical-stage biotechnology company that has developed a Phase 3 ready, intra-articular biologic drug derived from placental tissue. The lead product, MOTYS™, includes a host of beneficial growth factors with pre-clinical data that suggests potent anti-inflammatory, tissue-protective and regenerative capabilities pivotal to treating the progressive and degenerative disease of osteoarthritis..

Doron Therapeutics是一家临床阶段的生物技术公司，已开发出一种源自胎盘组织的3期就绪关节内生物药物。主要产品MOTYS™包括一系列有益的生长因子，临床前数据表明其具有强大的抗炎、组织保护和再生能力，对治疗骨关节炎的进行性和退行性疾病至关重要。。

About SPRIM Global Investments

关于SPRIM Global Investments

SPRIM Global Investments (SGI) is a leading health sciences venture capital firm with deep industry expertise and decades of operating experience across 17 countries. SGI invests in biotechnology, digital health and R&D service companies to commercialize the newest technologies and accelerate innovations that are the future of health around the world.Contact: .

SPRIM Global Investments（SGI）是一家领先的健康科学风险投资公司，在17个国家拥有深厚的行业专业知识和数十年的运营经验。SGI投资于生物技术、数字健康和研发服务公司，将最新技术商业化，并加速创新，这是世界各地健康的未来。联系人：。。

Media Contact:

媒体联系人：

Sarah Caley

莎拉·凯利

Head of Business Development and Strategy

业务发展和战略主管

Doron Therapeutics

多龙治疗学

info@dorontherapeutics.com

info@dorontherapeutics.com

Contact Information

联系方式

Sarah Caley

莎拉·凯利

Head of Business Development

info@dorontherapeutics.com

info@dorontherapeutics.com